Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reduced number of endothelial progenitor cells in adult patients with beta thalassemia major.

Annals of hematology·2026

Same author

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

Blood vessels, thrombosis & hemostasis·2026

Same author

Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Brain atrophy is associated with antiphospholipid antibody syndrome with and without vascular pathology.

Journal of the neurological sciences·2025

Same author

Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation.

Haematologica·2025

Same author

Interferon-α Inhibits NET Formation in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Sub-Population-Specific Manner.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Frontiers in platelet inhibition.

David Varon¹, Elai Shai, Galia Spectre

¹Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. dvaron@hadassah.org.il

Discovery Medicine

|December 31, 2009

Summary

Anti-platelet therapies, including aspirin and P2Y12 inhibitors, are crucial for cardiovascular care. Research highlights variable patient responses and bleeding risks, driving development towards personalized dosing and new drug therapies for improved outcomes.

Area of Science:

Cardiovascular Medicine
Pharmacology
Thrombosis Research

Background:

Anti-platelet drugs, like aspirin and P2Y12 inhibitors, are foundational in cardiovascular medicine.
Dual anti-platelet therapy is standard for acute events and secondary prevention, improving clinical outcomes.
Increased efficacy of multi-drug regimens is linked to a higher risk of bleeding, necessitating careful dosing considerations.

Purpose of the Study:

To review the current landscape of anti-platelet therapy in cardiovascular medicine.
To discuss the variability in patient response to anti-platelet agents and its implications.
To explore the development of new anti-platelet drugs and personalized dosing strategies.

Main Methods:

Literature review of anti-platelet drug efficacy and clinical outcomes.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Related Experiment Videos

Last Updated: Jun 17, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Analysis of studies reporting variable laboratory responses to aspirin and clopidogrel.

Examination of proposed mechanisms for response variability, including genetics and disease burden.

Overview of current drug development pipelines for anti-platelet agents.

Main Results:

Variable laboratory responses to aspirin and clopidogrel have been observed, correlating with clinical outcomes.
Genetic variability, disease burden, and other factors contribute to differential drug responses.
A lack of standardized testing methods hinders the assessment of anti-platelet drug response.
Numerous novel anti-platelet agents targeting various pathways are in development.

Conclusions:

Anti-platelet therapy is evolving towards combination regimens and personalized dose adjustments.
Future developments aim to optimize clinical outcomes by managing efficacy and bleeding risks.
Personalized anti-platelet dosing holds promise for improved patient management in cardiovascular medicine.